Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Impact Factor 13.965
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation Research

  • My alerts
  • Sign In
  • Join

  • Impact Factor 13.965
  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
MiniReview

Enhanced Angiotensin II Activity in Heart Failure

Reevaluation of the Counterregulatory Hypothesis of Receptor Subtypes

Lionel H. Opie, Michael N. Sack
Download PDF
https://doi.org/10.1161/hh0701.089175
Circulation Research. 2001;88:654-658
Originally published April 13, 2001
Lionel H. Opie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael N. Sack
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics

Jump to

  • Article
    • Abstract
    • Signaling Pathways
    • AT2 Receptor in Cardiac Growth
    • AT2 Receptor and Cardiac Apoptosis
    • AT2 Receptor and Cardiac Fibrosis
    • From Bench to Bedside
    • Conclusions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Abstract

Abstract—There are strong data favoring the pathogenic role of angiotensin II type 1 receptor (AT1) activation with subsequent promotion of myocyte growth and cardiac fibrosis in the development of cardiac hypertrophy and heart failure. An emerging hypothesis suggests that the activity of the angiotensin II type 2 receptor (AT2) may counterregulate AT1 receptor effects during cardiac development and during the evolution of cardiac hypertrophy and heart failure. In this review, we examine the potential role of AT2 activity in the context of this hypothesis. In contrast to the counterregulatory hypothesis, studies in mice with an overabundance of, or a deficiency in, the AT2 receptor do not suggest that AT2 signaling is essential for cardiac development. Moreover, the proposed antigrowth effects of AT2 receptor signaling in pathological cardiac hypertrophy could not be shown in two mice models both deficient in AT2 receptors. The role of AT2 receptor signaling in cardiac fibrosis is, however, still debatable because of conflicting data in the same two studies. In angiotensin II–evoked apoptosis in cardiomyocytes, the proposed proapoptotic role of AT2 activity could not be confirmed. Furthermore, in the progression from the bench to bedside, the results of two large clinical trials in heart failure, namely ELITE II and Val-HeFT, can be explained without ascribing a major protective role to the unopposed activity of the AT2 receptor in the failing myocardium. In this review, we conclude that the collective evidence does not strongly support a net beneficial effect of AT2 stimulation in the diseased myocardium.

  • angiotensin receptor subtypes
  • counterregulation
  • renin-angiotensin system
  • heart failure

Two of the most powerful cardiovascular regulators are the β-adrenergic and the renin-angiotensin system (RAS). The strength of the two systems is such that, between them, they virtually control cardiovascular physiology. The β-adrenergic system is concerned with the fight-or-flight reactions, achieving abrupt increases in heart rate and cardiac output, whereas in adult life, the RAS controls blood volume, peripheral vascular tone, and hence the blood pressure (Table 1⇓). Both systems are subject to counterregulatory balances, postulated to be overridden by sustained activation in heart failure. Overactivity of the β-adrenergic system is self-limited by the uncoupling, internalization, and inactivation of the β-adrenergic receptor. In contrast, the mechanism of autoregulation of angiotensin stimulation in heart failure is less well-defined (Table 1⇓). Recent reviews suggest that activity of the angiotensin II type 2 receptor (AT2) may counterbalance the putative detrimental effects of angiotensin II type 1 receptor (AT1) activation in heart failure via mediating opposite cellular functions.1 2

View this table:
  • View inline
  • View popup
Table 1.

How Angiotensin II and β1-Adrenergic Effects Interact and Contrast

To explore the putative counterregulatory role of AT2 receptor signaling, we need to define the role of AT1 signaling in the heart. It is already known that AT1 stimulation leads to vasoconstriction, cell growth, positive inotropy, catecholamine release, and increased aldosterone secretion with fibrosis, all deemed to have a detrimental component in cardiac hypertrophy and heart failure. Thus, to confer counterregulatory effects, AT2 receptor stimulation should oppose one or more of the phenotypic effects of AT1 receptor stimulation. In this review, we examine the putative individual components of AT2 receptor signaling in the heart, ie, in cardiac growth, apoptosis, and fibrosis. We also discuss the results of recent clinical trials aimed at specific inhibition of the RAS in heart failure. We conclude that these proposed counterregulatory effects may not be of major significance in the overall regulation of the RAS in cardiac hypertrophy and heart failure.

Signaling Pathways

Before describing the phenotypic response to the modulation of the AT2 receptor system in the myocardium, we will briefly review AT1 and AT2 receptor subtype signaling. These data regarding signal transduction could provide insight into the counterregulatory hypothesis. In response to mechanical stretch of neonatal cardiomyocytes, both AT1 and AT2 receptors are upregulated.3 AT1 receptor activates several well-defined paths, including vascular contraction mediated by inositol triphosphate (IP3) and release of calcium from the sarcoplasmic reticulum, whereas myocardial growth is mediated by protein kinase C (PKC) activity and a multiplicity of paths that lead to mitogen-activated protein (MAP) kinase activity. Furthermore, through a path that involves oxygen radicals and ceramide, nuclear factor (NF)-κB may be activated.4 The latter is a pleiotropic nuclear regulatory peptide promoting both beneficial and adverse effects.5 Some pathways linked to stimulation of the AT2 receptors are similar to AT1 effects.6 NF-κB activation may be involved, especially in vascular smooth muscle, which in turn could lead to growth, fibrosis, or apoptosis, in a context-dependent manner.4 The AT2 receptor may exert adverse effects during ischemia/reperfusion, mediated by IP3 and PKCε.7 There may also be a myocardial kinin protective path involving nitric oxide, bradykinin, and prostaglandins.2 8 A similar vascular kinin protective path is found in transgenic mice overexpressing the AT2 receptor.9 However, once bradykinin is formed, it might inhibit the formation of angiotensin II10 to limit the proposed beneficial counterregulatory effects.

AT2 Receptor in Cardiac Growth

In vascular smooth muscle cells, the AT2 receptor exerts an antiproliferative effect whereas the AT1 receptor promotes growth.2 In a variety of models of myocardial growth, both AT1 and AT2 receptors are upregulated.3 11 12 In neonatal rat cardiomyocytes, the antagonism of AT2 receptor signaling in response to a hypertrophic stimulus suggests that the AT2 receptor does mediate an antigrowth effect,13 as supported by an acute study of angiotensin-induced hypertrophic growth in rats.14 In contrast, when left ventricular hypertrophy (LVH) was induced by chronic infusion of angiotensin II in rats, losartan inhibited this process, showing the role of AT1 receptors, whereas AT2 receptor block neither changed the blood pressure nor the degree of ventricular hypertrophy.15 Finally, if the AT2 receptor has antigrowth effects, then its deletion by genetic ablation should lead to LVH in response to a pressure load. Two recent studies using independently generated AT2 receptor-null mice dispute this hypothesis (Table 2⇓). In the first study, targeted deletion of the AT2 receptor prevented LVH in response to aortic banding, and contractile function remained normal.16 In the second study, the heart-to-body weight ratio increased by ≈15% in both deletion and wild-type mice in response to increased aortic pressure.17 Collectively, these mice deletion studies challenge the antigrowth effect of AT2 receptor signaling. The apparently conflicting data in the neonatal cardiomyocyte model13 and the acute infusion studies14 may be outweighed by data from these receptor deletion studies. Furthermore, the counterregulatory hypothesis is not supported by the fact that no obvious abnormal cardiac developmental phenotype is evident in multiple mice with genetic manipulations of the AT1 and AT2 receptor subtypes (Table 2⇓).

View this table:
  • View inline
  • View popup
Table 2.

Effects on Cardiac Phenotype After the Genetic Manipulation of the AT1 and AT2 Receptors or of Cardiac RAS

AT2 Receptor and Cardiac Apoptosis

An alternative antigrowth effect could be in the promotion of programmed cell death (apoptosis). There are strong links between AT2 receptor activity and the augmentation of apoptosis in a variety of tissues, including vascular smooth muscle and endothelial cells, as well as fibroblasts, as outlined by Horiuchi et al.2 In contrast, proapoptotic effects of AT2 receptor signaling were not evident in two studies in cultured rat cardiomyocytes.18 19 In these studies, administration of angiotensin II provoked apoptosis that was inhibited by AT1 receptor blockade but not by the AT2 receptor blockade. Moreover, in mice with robust AT2 receptor expression, no evidence of augmented apoptosis was suggested.20 Hence, in the heart, the data do not support a counterregulatory role of the AT2 receptor in mediating antigrowth effects. Perhaps the paradigm of context-specific regulation is relevant regarding the significance of AT2 receptor signaling and apoptosis.

AT2 Receptor and Cardiac Fibrosis

Excess AT1 stimulation leads to left ventricular fibrosis.21 To counterregulate this effect, AT2 receptor activation should attenuate myocardial fibrosis. There is an antifibrotic effect of AT2 receptor stimulation on fibroblasts extracted from cardiomyopathic hamsters.22 This concept is supported by a study in AT2 receptor–deficient mice exposed to aortic banding. In this study, perivascular fibrosis was attenuated in genetically ablated mice compared with wild-type control mice.17 In a preliminary report, cardiac overexpression of AT2 receptor in mice attenuated cardiac fibrosis but not cardiac hypertrophy.23 In stark contrast, the AT2-deficient mice study by Senbonmatsu et al16 implies that AT2 activity is important for the left ventricular interstitial fibrotic response to pressure overload. A third view is that the cardiac AT2 receptor stimulation has little or no influence on myocardial fibrosis24 25 and that fibrosis more likely is related to the prevailing blood pressure.24 In support of this view, the degree of postinfarct myocardial fibrosis in rats was attenuated by AT1 blockade without any significant effects of added AT2 blockade.26 In humans, myocardial fibrosis can be regressed by angiotensin-converting enzyme (ACE) inhibition27 that presumably reduces stimulation of both AT1 and AT2 receptors. Therefore, the relationship between AT2 receptor activity and fibrosis in the myocardium has not been definitively clarified. Moreover, an important recent point is that AT2 receptor stimulation can have bidirectional effects in different tissues, decreasing collagen synthesis in cultured fibroblasts but increasing synthesis in mesangial cells.28

From Bench to Bedside

It is now firmly established that inhibition of ACE does have a markedly beneficial effect in the treatment of heart failure. ACE inhibitor therapy, however, does not completely block angiotensin II production, and in some patients, angiotensin II levels remain elevated, in part, because of the conversion of angiotensin I to angiotensin II by chymase activity.29 Thus, continued AT2 receptor stimulation could occur. This hypothesis is indirectly supported by the relative upregulation of the AT2 receptor in human heart failure,30 31 although this finding is controversial.32 33 Currently, no therapeutic agents that specifically act on the AT2 receptor are approved for clinical trials. However, numerous AT1 receptor blockers are available that could hypothetically shunt the activity of the cardiac RAS toward stimulation of the beneficial AT2 receptor.

Two separate clinical approaches evaluate this hypothesis. First, ACE inhibitor therapy was directly compared with AT1 receptor antagonist therapy in a randomized controlled clinical study, ELITE II, that was adequately powered34 in contrast to the underpowered first ELITE trial. In ELITE II, the ACE inhibitor captopril was compared with the AT1 blocker losartan in 3152 patients aged 60 years or older, with endpoints of all-cause mortality, sudden death, or resuscitated arrest. No significant differences were found, suggesting that the beneficial effect of these two classes of agents were both via the inhibition of AT1 receptor signaling and that beneficial AT2 signaling played no role. Second, the addition of the AT1 receptor blocker valsartan to preexisting therapy in the Val-HeFT study meant that the drug classes were effectively combined and compared with ACE inhibitor therapy alone.35 The preliminary report on 5009 patients with heart failure, mostly New York Heart Association classification grade II and grade III, showed unchanged rate of mortality but reduced rate of morbidity, including hospitalization. In other experimental and human heart failure studies, the combination of an AT1 blocker plus ACE inhibition resulted in a greater reduction in angiotensin II levels versus ACE inhibition therapy alone.36 37 Collectively, these data suggest that if combined RAS antagonist therapy is more successful in heart failure than individual antagonists alone, it is probably due to the combinatorial decrease in angiotensin II levels and less likely that increased stimulation of the AT2 receptor plays a major beneficial role.

Conclusions

Angiotensin II activation promotes adverse remodeling in experimental heart failure, and these effects can be attenuated by ACE inhibition and AT1 receptor blockade.26 38 39 40 This suggests major dependency on the AT1 receptor, without necessarily having to invoke any specific protective role of the AT2 receptor.1 We do, however, believe that potential counterregulation of the proposed AT1-induced perivascular fibrosis by AT2 activity17 deserves further investigation. Furthermore, different effects of increased AT2 activity in different tissues need to be considered.28 41 The overall data do not argue convincingly for a major compulsory protective role of AT2 receptors in heart failure treated by AT1 blockade, despite the strong evidence in specific models.8 26 Rather, the totality of evidence, both clinical and laboratory, is that activity of the AT1 receptor is crucial in the progression of heart failure.

Moving from bench to bedside, there is no need to invoke the counterregulation hypothesis concerning the proposed benefits of increased AT2 activity to explain the results of these large clinical trials in heart failure. It appears that the concept of AT1 counterregulation by AT2 receptor activity is too simplistic to account for all the apparently conflicting data. We acknowledge that some downstream messengers of AT1 receptor activity unequivocally oppose those of the AT2 receptors, for example, AT1-induced vasoconstriction versus kinin-mediated vasodilation. Further work is now required to understand why paths communal to both AT1 and AT2 signaling, such as those involving NF-κB, may lead to either growth or apoptosis.

Acknowledgments

The Heart Failure Group of the Hatter Institute is supported by the Medical Research Council of South Africa and by unrestricted grants from Roche Pharmaceuticals (Chair of Cellular Cardiology) and Servier Laboratories (Senior Lecturer in Cellular Cardiology).

Footnotes

  • Original received December 15, 2000; revision received February 23, 2001; accepted February 23, 2001.

  • © 2001 American Heart Association, Inc.

References

  1. ↵
    Sadoshima J. Cytokine actions of angiotensin II. Circ Res. 2000;86:1187–1189.
    OpenUrlFREE Full Text
  2. ↵
    Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension. 1999;33:613–621.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Kijima K, Matsubara H, Murasawa S, Maruyama K, Mori Y. Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes. Circ Res. 1996;79:887–897.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J. Angiotensin II activates nuclear transcription factor-κB through AT1 and AT2 in vascular smooth muscle cells: molecular mechanisms. Circ Res. 2000;86:1266–1272.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Schmidt A, Stern D. Hyperinsulinemia and vascular dysfunction: the role of nuclear factor-κB, yet again. Circ Res. 2000;87:722–724.
    OpenUrlFREE Full Text
  6. ↵
    Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res. 1998;83:1182–1191.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    Xu Y, Clanachan A, Jugdutt B. Enhanced expression of angiotensin II type 2 receptor, inositol 1,4,5-trisphosphate receptor, and protein kinase Cε during cardioprotection induced by angiotensin II type 2 receptor blockade. Hypertension. 2000;35:506–510.
    OpenUrl
  8. ↵
    Jalowy A, Schulz R, Dorge H, Behrends M, Heusch G. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. J Am Coll Cardiol. 1998;32:1787–1796.
    OpenUrlCrossRefPubMed
  9. ↵
    Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Taki S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest. 1999;104:925–935.
    OpenUrlCrossRefPubMed
  10. ↵
    Sato M, Engelman RM, Otani J, Maulik N, Rousou J, Flack J, Deaton D, Das D. Myocardial protection by preconditioning of heart with losartan, angiotensin-II type 1-receptor blocker. Circulation. 2000;102(suppl III):III-346–III-351.
  11. ↵
    Suzuki J, Matsubara H, Urakami M, Inada M. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy. Circ Res. 1993;73:439–447.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest. 1995;95:46–54.
  13. ↵
    Booz GW, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin II–induced cardiomyocyte hypertrophy. Hypertension. 1996;28:635–640.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Bartunek J, Weinberg EO, Tajima M, Rohrbach S, Lorell BH. Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts. Circulation. 1999;99:22–25.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Li JS, Touyz RH, Schiffrin E. Effects of AT1 and AT2 angiotensin receptor antagonists in angiotensin II–infused rats. Hypertension. 1998;31(pt 2):487–492.
  16. ↵
    Senbonmatsu T, Ichihara S, Price E Jr, Gaffney A, Inagami T. Evidence for angiotensin II type 2 receptor-mediated cardiac myocyte enlargement during in vivo pressure overload. J Clin Invest. 2000;106:R25–R29.
  17. ↵
    Akishita M, Iwai M, Wu L, Zhang L, Ouchi Y, Dzau V, Horiuchi M. Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic binding in mice. Circulation. 2000;102:1684–1689.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, Anversa P. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol. 1997;29:859–870.
    OpenUrlCrossRefPubMed
  19. ↵
    Cigola E, Kajstura J, Li B, Meggs LG, Anversa P. Angiotensin II activates programmed myocyte cell death in vitro. Exp Cell Res. 1997;231:363–371.
    OpenUrlCrossRefPubMed
  20. ↵
    Masaki H, Kurihara T, Yamaki A, Inomata N, Nozawa Y, Mori Y, Murasawa S, Kizima K, Maruyama K, Horiuchi M. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J Clin Invest. 1998;101:527–535.
    OpenUrlCrossRefPubMed
  21. ↵
    Varo N, Iraburu MJ, Varela M, Lopez B, Etayo JC, Diez J. Chronic AT1 blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension. 2000;35:1197–1202.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, Maruyma K, Masaki H, Tsutumi Y, Shibazaki Y. Angiotensin type II receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation. 1997;96:3954–3962.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Kurisu S, Sugino H, Ozono R, Oshima T, Kambe M, Kajiyama G, Teranishi Y, Ogawa K, Masaki H, Matsubara H. Cardiac overexpression of type 2 Ang II receptor in transgenic mice attenuates cardiac fibrosis but not cardiac hypertrophy. Hypertension. 1999;34:331. Abstract.
    OpenUrl
  24. ↵
    Bishop J, Kiernan L, Montgomery H, Gohlke P, McEwan JR. Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats. Cardiovasc Res. 2000;47:57–67.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner H-R, Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension. 2000;35:985–991.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Liu Y-H, Yang Z-P, Sharov VG, Nass O, Sabbah HN, Petersen E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type I receptor antagonists in rats with heart failure. J Clin Invest. 1997;99:1926–1935.
    OpenUrlCrossRefPubMed
  27. ↵
    Brilla C, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388–1393.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Mifune M, Sasamura H, Shimizu-Hirota R, Miyazaki H, Saruta T. Angiotensin II type 2 receptors stimulate collagen synthesis in cultured vascular smooth muscle cells. Hypertension. 2000;36:845–850.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II–forming pathways in normal and failing human hearts. Circ Res. 1990;66:883–890.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Tsutsumi Y, Mtasubara H, Ohkubo N, Mori Y, Nozawa Y, Murasawa S, Kajima K, Maruyama K, Masaki H, Moriguchi Y. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res. 1998;83:1035–1046.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    Matsumoto T, Ozono R, Oshima T, Matsuura H, Sueda T, Kajiyama G, Kambe M. Type 2 angiotensin II receptor is downregulated in cardiomyocytes of patients with heart failure. Cardiovasc Res. 2000;46:73–81.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    Haywood GA, Gullestad L, Katsuya T, Hutchinson HG, Pratt RE, Horiuchi M, Fowler MB. AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation. 1997;95:1201–1206.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Regitz-Zagrosek V, Friedel N, Heymann A, Neuss M, Rolfs A, Steffen C, Hildebrandt A, Hetzer R, Fleck E. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation. 1995;91:1461–1471.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    Pitt B, Poole-Wilson P, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582–1587.
    OpenUrlCrossRefPubMed
  35. ↵
    Cohn JN, Tognoni G. Effect of the angiotensin receptor blocker valsartan on morbidity and mortality in heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2000;102(suppl II):2672-b. Abstract. See http://circ.ahajournals.org.
  36. ↵
    Ménard J, Campbell DJ, Zaizi M, Gonzales M-F. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight and renin in spontaneously hypertensive rats. Circulation. 1997;96:3072–3078.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J. The RESOLVD pilot study investigators. Comparison of candesartan, enalapril and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation. 1999;100:1056–1064.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    Pfeffer MA, Lamas GA, Vaughan DE, Parish AF, Braunwald E. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med. 1988;319:80–86.
    OpenUrlCrossRefPubMed
  39. ↵
    van Kats J, Duncker D, Haitsma D, Schuijt M, Niebuur R, Stubenitsky R, Boomsma F, Schalekamp M, Verdouw P, Danser A. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation. 2000;102:1556–1563.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Miki T, Iura T, Tsuchida A, Nakano A, Hasegawa T, Fukuma T, Shimamoto K. Cardioprotective mechanism of ischemic preconditioning is impaired by postinfarct ventricular remodeling through angiotensin II type 1 receptor activation. Circulation. 2000;102:458–463.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest. 1995;95:651–657.
  42. Vatner D, Knight D, Homcy C, Vatner S, Young M. Subtypes of β-adrenergic receptors in bovine coronary arteries. Circ Res. 1986;59:463–473.
    OpenUrlAbstract/FREE Full Text
  43. Kilts J, Gerhardt M, Richardson M, Sreeram G, Burkhard Mackensen G, Grocott H, White W, Davis R, Newman M, Reves J. β2-Adrenergic and several other G protein–coupled receptors in human atrial membranes activate both Gs and Gi. Circ Res. 2000;87:705–709.
    OpenUrlAbstract/FREE Full Text
  44. Harada K, Komuro I, Shiojima I, Hayashi D, Kudoh S, Mizuno T, Kijima K, Matsubara H, Sugaya T, Murakami K. Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation. 1998;97:1952–1959.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation Research
April 13, 2001, Volume 88, Issue 7
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Abstract
    • Signaling Pathways
    • AT2 Receptor in Cardiac Growth
    • AT2 Receptor and Cardiac Apoptosis
    • AT2 Receptor and Cardiac Fibrosis
    • From Bench to Bedside
    • Conclusions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Enhanced Angiotensin II Activity in Heart Failure
    Lionel H. Opie and Michael N. Sack
    Circulation Research. 2001;88:654-658, originally published April 13, 2001
    https://doi.org/10.1161/hh0701.089175

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation Research.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Enhanced Angiotensin II Activity in Heart Failure
    (Your Name) has sent you a message from Circulation Research
    (Your Name) thought you would like to see the Circulation Research web site.
  • Share on Social Media
    Enhanced Angiotensin II Activity in Heart Failure
    Lionel H. Opie and Michael N. Sack
    Circulation Research. 2001;88:654-658, originally published April 13, 2001
    https://doi.org/10.1161/hh0701.089175
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Heart Failure and Cardiac Disease
    • Remodeling
    • Heart Failure
  • Basic, Translational, and Clinical Research
    • ACE/Angiotensin Receptors/Renin Angiotensin System

Circulation Research

  • About Circulation Research
  • Editorial Board
  • Instructions for Authors
  • Abstract Supplements
  • AHA Statements and Guidelines
  • Permissions
  • Reprints
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
3355 Keswick Rd
Main Bldg 103
Baltimore, MD 21211
CircRes@circresearch.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured